ViewRay, Inc. (VRAY) Research
ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical facilities, including university research and teaching hospitals, local community hospitals, private medical practices, government institutions, and independent cancer treatment centers. MRIdian systems are sold to these clients via ViewRay's direct sales force and through its established distribution channels. The company was founded in 2004 and operates out of its main office in Oakwood, Ohio.
Market snapshot
- Symbol
- VRAY
- Price
- $0.03
- Day change
- 0.00%
- Market cap
- $4.6M
- P/E ratio
- -0.04x
- 52-week range
- 0.0245-0.0397
- Sector
- Healthcare
- Industry
- Medical - Devices
- Analyst price target
- $6.25
Peer companies
Recent insider activity
- Shah Sanket — A-Award (350000 shares) on 2023-07-15
- Shah Sanket — S-Sale (30364 shares) on 2023-07-21
- Podbelski Adam Andrew — A-Award (350000 shares) on 2023-07-15
- Podbelski Adam Andrew — S-Sale (89901 shares) on 2023-07-17
- Shah Sanket — trade (0 shares) on 2023-07-15
Open ViewRay, Inc. (VRAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.